Dr. Alachkar's research focuses on recurrent glomerular diseases post kidney transplantation. In particular, she has been studying recurrent FSGS post kidney transplant in several, partially NIH funded, prospective research projects that focuses on circulating factors associate with recurrent FSGS and new therapies of recurrent FSGS; in addition to the outcome of the disease. Also, Dr. Alachkar is the Chair of Banff recurrent GN working group that focus on the pathological changes of recurrent GN.
Dr. Alachkar's other research focus is incompatible living and diseases donor transplant. She has several ongoing research studies that focus on AMR and the outcome of patients with positive donor specific antibodies.

We are devoted to developing and deploying cutting edge technologies that can be used to define human immune responses. Much of our work leverages ‘next generation’ DNA sequencing, which enables massively parallel molecular measurements. Examples of our technologies include: - bacteriophage display of synthetic peptidome libraries for comprehensive, quantitative profiling of antibodies; - display of ORFeome libraries for antigen discovery, protein-protein interaction studies, and drug target identification; - ultrasensitive, multiplex RNA quantification techniques to monitor gene expression and detect microbes; - pooled genetic screening to elucidate immune cell function and identify new therapeutic targets. The Larman Laboratory uses these and other approaches to identify opportunities for monitoring and manipulating immune responses.

At the Suman Paul laboratory, we are focused on developing new antibodies and cell therapies for cancer treatment. Our team of researchers are dedicated to identifying novel targets, mechanisms for cancer therapy and developing innovative solutions to improve patient outcomes. We work closely with basic science researchers and clinicians to accelerate the translation of our discoveries into clinical practice.

Work in the Rachel Damico Lab explores topics within the fields of vascular biology and pulmonary medicine, with a focus on acute lung injury and apoptosis in lung diseases. Our studies have included examining idiopathic and scleroderma-associated pulmonary arterial hypertension, vascular receptor autoantibodies, and the link between inflammation and the Warburg phenomenon in patients with pulmonary arterial hypertension. We have also researched the inhibitory factor of macrophage migration and its governing of endothelial cell sensitivity to LPS-induced apoptosis.